Nevro (NYSE:NVRO) Downgraded to Sell at StockNews.com

StockNews.com lowered shares of Nevro (NYSE:NVROFree Report) from a hold rating to a sell rating in a research report report published on Tuesday morning.

Other equities analysts also recently issued research reports about the company. Canaccord Genuity Group downgraded Nevro from a buy rating to a hold rating and set a $23.00 price target for the company. in a research report on Thursday, December 21st. Truist Financial raised their price target on Nevro from $22.00 to $23.00 and gave the stock a hold rating in a research report on Friday, December 22nd. Canaccord Genuity Group reissued a hold rating and set a $23.00 price target on shares of Nevro in a research report on Thursday, December 21st. JPMorgan Chase & Co. decreased their price objective on Nevro from $23.00 to $18.00 and set a neutral rating on the stock in a report on Thursday, November 2nd. Finally, Morgan Stanley decreased their price objective on Nevro from $23.00 to $18.00 and set an equal weight rating on the stock in a report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of Hold and a consensus target price of $24.00.

Get Our Latest Stock Analysis on Nevro

Nevro Stock Up 7.2 %

NYSE NVRO opened at $17.61 on Tuesday. Nevro has a 1-year low of $13.98 and a 1-year high of $40.56. The business has a 50 day moving average price of $19.41 and a 200 day moving average price of $18.95. The company has a quick ratio of 5.01, a current ratio of 6.55 and a debt-to-equity ratio of 0.66.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. raised its position in Nevro by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 280,528 shares of the medical equipment provider’s stock valued at $6,037,000 after purchasing an additional 3,860 shares during the period. M&T Bank Corp raised its position in Nevro by 29.9% in the fourth quarter. M&T Bank Corp now owns 40,639 shares of the medical equipment provider’s stock valued at $875,000 after purchasing an additional 9,345 shares during the period. Natixis Advisors L.P. increased its position in shares of Nevro by 119.1% during the fourth quarter. Natixis Advisors L.P. now owns 28,294 shares of the medical equipment provider’s stock worth $608,000 after acquiring an additional 15,380 shares during the last quarter. Truist Financial Corp increased its position in shares of Nevro by 27.3% during the fourth quarter. Truist Financial Corp now owns 38,496 shares of the medical equipment provider’s stock worth $828,000 after acquiring an additional 8,247 shares during the last quarter. Finally, Semanteon Capital Management LP purchased a new stake in shares of Nevro during the fourth quarter worth about $1,122,000. 95.52% of the stock is owned by hedge funds and other institutional investors.

About Nevro

(Get Free Report)

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems.

Recommended Stories

Analyst Recommendations for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.